Is the Fun Over for Orexigen (OREX)? (VVUS) (ARNA)

Article Stock Quotes (3) Comments (0)

Shares of Orexigen Therapeutics (Nasdaq: OREX) ran up into the approval VIVUS (Nasdaq: VVUS) Qsymia and Arena's (Nasdaq: ARNA) Belviq, which happened within weeks of each other. Both are new weight-management drugs, the first approved in the U.S. in the last 13 years.

Now, Orexigen holders will still need to wait about two years before its proposed obesity pill, Contrave, is approved.

So, with Orexigen starting May at around $3.50, will investors and traders be anticipating a 50 percent drop in the shares? Or will Arena and VIVUS be enough to sustain hope for the next 18 to 42 months?

Orexigen is trading 3.2 percent lower at the start Thursday, looking at a third day of losses.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Tesla (TSLA) Ramps Higher (GM)
• Arena (ARNA) Slumps as Consumer Reports Says to 'Skip' Belviq
• No Split for Alcatel (ALU) as CEO Combes Looks to 'Slim-Down' Operations

Create E-mail Alert Related Categories

Insiders' Blog, Momentum Movers

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?